Dr. Alok Kanojia (Dr. K)

Here's the anxiolytic effect.

So now we're looking at and y'all can just sort of see like how far to the left these are.

So you can sort of see, relatively speaking, like this is looking at psilocybin.

You know, is psilocybin effective for is it more effective for depression?

Is it more effective for anxiety?

So here's a negative, which means symptom improvement.

So this is basically looking at each of the psychedelics and looking at which effects they have.

This is looking at the conditions in which psychedelics are effective for the condition.

Do you all understand the difference?

And then we also have studies on things like alcoholism, where you'll notice that when we look at something like LSD for alcoholism,

And psilocybin for alcoholism, what we start to see is that these are a lot more crossing the midline, right?

So this doesn't seem to be as effective for substance use disorders as it is for something like treatment-resistant depression.

So the key thing here is here's LSD for alcoholism, and it crosses the midline, which means it's not very statistically significant.

Here's psilocybin for alcoholism.

This one crosses the midline.

These two don't.

So this appears like psilocybin is more effective for alcoholism than LSD is.

And then we can look at MDMA for PTSD.

So this is super exciting as well because we don't have great pharmacologic agents for PTSD, right?

We have to do a lot of physiologic rewiring.